Generics BRIC (Brazil, Russia, India, China) Industry Guide 2017-2021

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the BRIC generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

– Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $81,615.2 million in 2016. Russia was the fastest growing country with a CAGR of 15.1% over the 2012-16 period.

– Within the generics industry, China is the leading country among the BRIC nations with market revenues of $57,010.8 million in 2016. This was followed by India, Russia and Brazil with a value of $12,654.0, $6,617.8, and $5,332.6 million, respectively.

– China is expected to lead the generics industry in the BRIC nations with a value of $87,161.6 million in 2021, followed by India, Russia, Brazil with expected values of $18,196.7, $12,616.9 and $10,359.5 million, respectively.

Scope

– Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market

– Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume

– Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons to buy

- What was the size of the BRIC generics market by value in 2016?

- What will be the size of the BRIC generics market in 2021?

- What factors are affecting the strength of competition in the BRIC generics market?

- How has the market performed over the last five years?

- How large is the BRIC generics market in relation to its regional counterparts?

Table of Contents

Table of Contents

Introduction 11

What is this report about? 11

Who is the target reader? 11

How to use this report 11

Definitions 11

BRIC Generics 12

Industry Outlook 12

Generics in Brazil 15

Market Overview 15

Market Data 16

Market Segmentation 18

Market outlook 19

Five forces analysis 21

Macroeconomic indicators 27

Generics in China 29

Market Overview 29

Market Data 30

Market Segmentation 32

Market outlook 33

Five forces analysis 35

Macroeconomic indicators 41

Generics in India 43

Market Overview 43

Market Data 44

Market Segmentation 46

Market outlook 47

Five forces analysis 49

Macroeconomic indicators 55

Generics in Russia 57

Market Overview 57

Market Data 58

Market Segmentation 60

Market outlook 61

Five forces analysis 63

Macroeconomic indicators 69

Company Profiles 71

Leading Companies 71

Appendix 108

Methodology 108

About MarketLine 109

List of Tables

List of Tables

Table 1: BRIC generics industry, revenue($m), 2012-21

Table 2: BRIC generics industry, revenue($m), 2012-16

Table 3: BRIC generics industry, revenue($m), 2016-21

Table 4: Brazil generics market value: $ million, 2012-16

Table 5: Brazil generics market volume: % of total pharma volume, 2012-16

Table 6: Brazil generics market geography segmentation: $ million, 2016

Table 7: Brazil generics market value forecast: $ million, 2016-21

Table 8: Brazil generics market volume forecast: % of total pharma volume, 2016-21

Table 49: Brazil size of population (million), 2012-16

Table 50: Brazil gdp (constant 2005 prices, $ billion), 2012-16

Table 51: Brazil gdp (current prices, $ billion), 2012-16

Table 52: Brazil inflation, 2012-16

Table 53: Brazil consumer price index (absolute), 2012-16

Table 54: Brazil exchange rate, 2012-16

Table 9: China generics market value: $ billion, 2012-16

Table 10: China generics market volume: % of total pharma volume, 2012-16

Table 11: China generics market geography segmentation: $ billion, 2016

Table 12: China generics market value forecast: $ billion, 2016-21

Table 13: China generics market volume forecast: % of total pharma volume, 2016-21

Table 14: China size of population (million), 2012-16

Table 15: China gdp (constant 2005 prices, $ billion), 2012-16

Table 16: China gdp (current prices, $ billion), 2012-16

Table 17: China inflation, 2012-16

Table 18: China consumer price index (absolute), 2012-16

Table 19: China exchange rate, 2012-16

Table 20: India generics market value: $ million, 2012-16

Table 21: India generics market volume: % of total pharma volume, 2012-16

Table 22: India generics market geography segmentation: $ million, 2016

Table 23: India generics market value forecast: $ million, 2016-21

Table 24: India generics market volume forecast: % of total pharma volume, 2016-21

Table 25: India size of population (million), 2012-16

Table 26: India gdp (constant 2005 prices, $ billion), 2012-16

Table 27: India gdp (current prices, $ billion), 2012-16

Table 28: India inflation, 2012-16

Table 29: India consumer price index (absolute), 2012-16

Table 30: India exchange rate, 2012-16

Table 31: Russia generics market value: $ million, 2012-16

Table 32: Russia generics market volume: % of total pharma volume, 2012-16

Table 33: Russia generics market geography segmentation: $ million, 2016

Table 34: Russia generics market value forecast: $ million, 2016-21

Table 35: Russia generics market volume forecast: % of total pharma volume, 2016-21

Table 36: Russia size of population (million), 2012-16

Table 37: Russia gdp (constant 2005 prices, $ billion), 2012-16

Table 38: Russia gdp (current prices, $ billion), 2012-16

Table 39: Russia inflation, 2012-16

Table 40: Russia consumer price index (absolute), 2012-16

Table 41: Russia exchange rate, 2012-16

Table 42: Ache Laboratorios Farmaceuticos SA: key facts

Table 43: EMS SA: key facts

Table 44: Sanofi SA: key facts

Table 45: Sanofi SA: key financials ($)

Table 46: Sanofi SA: key financials (€)

Table 47: Sanofi SA: key financial ratios

Table 48: Eurofarma Laboratorios SA: key facts

Table 55: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 56: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)

Table 57: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 58: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 59: Mylan N.V.: key facts

Table 60: Mylan N.V.: key financials ($)

Table 61: Mylan N.V.: key financial ratios

Table 62: Novartis AG: key facts

Table 63: Novartis AG: key financials ($)

Table 64: Novartis AG: key financial ratios

Table 65: Aurobindo Pharma Limited: key facts

Table 66: Aurobindo Pharma Limited: key financials ($)

Table 67: Aurobindo Pharma Limited: key financials (A$)

Table 68: Aurobindo Pharma Limited: key financial ratios

Table 69: Cipla Limited: key facts

Table 70: Cipla Limited: key financials ($)

Table 71: Cipla Limited: key financials (Rs.)

Table 72: Cipla Limited: key financial ratios

Table 73: Lupin Ltd: key facts

Table 74: Lupin Ltd: key financials ($)

Table 75: Lupin Ltd: key financials (Rs.)

Table 76: Lupin Ltd: key financial ratios

Table 77: Sun Pharmaceutical Industries Ltd: key facts

Table 78: Sun Pharmaceutical Industries Ltd: key financials ($)

Table 79: Sun Pharmaceutical Industries Ltd: key financials (Rs.)

Table 80: Sun Pharmaceutical Industries Ltd: key financial ratios

Table 81: Abbott Laboratories: key facts

Table 82: Abbott Laboratories: key financials ($)

Table 83: Abbott Laboratories: key financial ratios

Table 84: Krka, d. d., Novo mesto: key facts

Table 85: Krka, d. d., Novo mesto: key financials ($)

Table 86: Krka, d. d., Novo mesto: key financials (€)

Table 87: Krka, d. d., Novo mesto: key financial ratios

Table 88: Teva Pharmaceutical Industries Limited: key facts

Table 89: Teva Pharmaceutical Industries Limited: key financials ($)

Table 90: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures

List of Figures

Figure 1: BRIC generics industry, revenue($m), 2012-21

Figure 2: BRIC generics industry, revenue($m), 2012-16

Figure 3: BRIC generics industry, revenue($m), 2016-21

Figure 4: Brazil generics market value: $ million, 2012-16

Figure 5: Brazil generics market volume: % of total pharma volume, 2012-16

Figure 6: Brazil generics market geography segmentation: % share, by value, 2016

Figure 7: Brazil generics market value forecast: $ million, 2016-21

Figure 8: Brazil generics market volume forecast: % of total pharma volume, 2016-21

Figure 9: Forces driving competition in the generics market in Brazil, 2016

Figure 10: Drivers of buyer power in the generics market in Brazil, 2016

Figure 11: Drivers of supplier power in the generics market in Brazil, 2016

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016

Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2016

Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2016

Figure 15: China generics market value: $ billion, 2012-16

Figure 16: China generics market volume: % of total pharma volume, 2012-16

Figure 17: China generics market geography segmentation: % share, by value, 2016

Figure 18: China generics market value forecast: $ billion, 2016-21

Figure 19: China generics market volume forecast: % of total pharma volume, 2016-21

Figure 20: Forces driving competition in the generics market in China, 2016

Figure 21: Drivers of buyer power in the generics market in China, 2016

Figure 22: Drivers of supplier power in the generics market in China, 2016

Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2016

Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2016

Figure 25: Drivers of degree of rivalry in the generics market in China, 2016

Figure 26: India generics market value: $ million, 2012-16

Figure 27: India generics market volume: % of total pharma volume, 2012-16

Figure 28: India generics market geography segmentation: % share, by value, 2016

Figure 29: India generics market value forecast: $ million, 2016-21

Figure 30: India generics market volume forecast: % of total pharma volume, 2016-21

Figure 31: Forces driving competition in the generics market in India, 2016

Figure 32: Drivers of buyer power in the generics market in India, 2016

Figure 33: Drivers of supplier power in the generics market in India, 2016

Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2016

Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2016

Figure 36: Drivers of degree of rivalry in the generics market in India, 2016

Figure 37: Russia generics market value: $ million, 2012-16

Figure 38: Russia generics market volume: % of total pharma volume, 2012-16

Figure 39: Russia generics market geography segmentation: % share, by value, 2016

Figure 40: Russia generics market value forecast: $ million, 2016-21

Figure 41: Russia generics market volume forecast: % of total pharma volume, 2016-21

Figure 42: Forces driving competition in the generics market in Russia, 2016

Figure 43: Drivers of buyer power in the generics market in Russia, 2016

Figure 44: Drivers of supplier power in the generics market in Russia, 2016

Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016

Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2016

Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2016

Figure 48: Sanofi SA: revenues & profitability

Figure 49: Sanofi SA: assets & liabilities

Figure 50: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 51: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 52: Mylan N.V.: revenues & profitability

Figure 53: Mylan N.V.: assets & liabilities

Figure 54: Novartis AG: revenues & profitability

Figure 55: Novartis AG: assets & liabilities

Figure 56: Aurobindo Pharma Limited: revenues & profitability

Figure 57: Aurobindo Pharma Limited: assets & liabilities

Figure 58: Cipla Limited: revenues & profitability

Figure 59: Cipla Limited: assets & liabilities

Figure 60: Lupin Ltd: revenues & profitability

Figure 61: Lupin Ltd: assets & liabilities

Figure 62: Sun Pharmaceutical Industries Ltd: revenues & profitability

Figure 63: Sun Pharmaceutical Industries Ltd: assets & liabilities

Figure 64: Abbott Laboratories: revenues & profitability

Figure 65: Abbott Laboratories: assets & liabilities

Figure 66: Krka, d. d., Novo mesto: revenues & profitability

Figure 67: Krka, d. d., Novo mesto: assets & liabilities

Figure 68: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 69: Teva Pharmaceutical Industries Limited: assets & liabilities

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports